Clinical Trials Directory

Trials / Completed

CompletedNCT02887495

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

Status
Completed
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
George Washington University · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

Conditions

Timeline

Start date
2014-07-01
Primary completion
2022-02-02
Completion
2022-02-02
First posted
2016-09-02
Last updated
2022-07-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02887495. Inclusion in this directory is not an endorsement.

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma) (NCT02887495) · Clinical Trials Directory